{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:12:56Z","timestamp":1771575176358,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00417-025-07025-y","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:08Z","timestamp":1762498328000},"page":"489-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chlorhexidine 0.02% treatment for refractory blepharoconjunctivitis"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1027-3139","authenticated-orcid":false,"given":"Eran","family":"Greenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"Nemet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fani","family":"Segev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaf","family":"Friehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"7025_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S1542-0124(12)70624-9","volume":"7","author":"TP O\u2019Brien","year":"2009","unstructured":"O\u2019Brien TP (2009) The role of bacteria in blepharitis. Ocular Surf 7:S21\u2013S22. https:\/\/doi.org\/10.1016\/S1542-0124(12)70624-9","journal-title":"Ocular Surf"},{"key":"7025_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/S00417-009-1039-0","volume":"247","author":"Y Yactayo-Miranda","year":"2009","unstructured":"Yactayo-Miranda Y, Ta CN, He L et al (2009) A prospective study determining the efficacy of topical 0.5% Levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 247:993\u2013998. https:\/\/doi.org\/10.1007\/S00417-009-1039-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7025_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1185\/03007995.2010.539603","volume":"27","author":"GL Torkildsen","year":"2011","unstructured":"Torkildsen GL, Cockrum P, Meier E et al (2011) Evaluation of clinical efficacy and safety of tobramycin\/dexamethasone ophthalmic suspension 0.3%\/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis\/blepharoconjunctivitis. Curr Med Res Opin 27:171\u2013178. https:\/\/doi.org\/10.1185\/03007995.2010.539603","journal-title":"Curr Med Res Opin"},{"key":"7025_CR4","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.2147\/OPTH.S52474","volume":"7","author":"K Hosseini","year":"2013","unstructured":"Hosseini K, Hutcheson J, Lindstrom RL (2013) A phase III clinical study to evaluate the efficacy of combined Azithromycin and dexamethasone in the treatment of blepharoconjunctivitis. Clin Ophthalmol 7:2225\u20132234. https:\/\/doi.org\/10.2147\/OPTH.S52474","journal-title":"Clin Ophthalmol"},{"key":"7025_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00417-003-0742-5","volume":"241","author":"H de Mi\u00f1o Kaspar","year":"2003","unstructured":"de Mi\u00f1o Kaspar H, Shriver EM, Nguyen EV et al (2003) Risk factors for antibiotic-resistant conjunctival bacterial flora in patients undergoing intraocular surgery. Graefes Arch Clin Exp Ophthalmol 241:730\u2013733. https:\/\/doi.org\/10.1007\/s00417-003-0742-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7025_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/1120672119854985","volume":"30","author":"A de Paula","year":"2020","unstructured":"de Paula A, Oliva G, Barraquer RI, de la Paz MF (2020) Prevalence and antibiotic susceptibility of bacteria isolated in patients affected with blepharitis in a tertiary eye centre in Spain. Eur J Ophthalmol 30:991\u2013997. https:\/\/doi.org\/10.1177\/1120672119854985","journal-title":"Eur J Ophthalmol"},{"key":"7025_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics12050798","volume":"12","author":"HM Abbood","year":"2023","unstructured":"Abbood HM, Hijazi K, Gould IM (2023) Chlorhexidine resistance or Cross-Resistance. That Is Question Antibiot 12:1\u201317. https:\/\/doi.org\/10.3390\/antibiotics12050798","journal-title":"That Is Question Antibiot"},{"key":"7025_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ajic.2010.06.022","volume":"38","author":"MJ Anderson","year":"2010","unstructured":"Anderson MJ, Horn ME, Lin YC et al (2010) Efficacy of concurrent application of chlorhexidine gluconate and povidone iodine against six nosocomial pathogens. Am J Infect Control 38:826\u2013831. https:\/\/doi.org\/10.1016\/j.ajic.2010.06.022","journal-title":"Am J Infect Control"},{"issue":"11","key":"7025_CR9","first-page":"951","volume":"6","author":"LR Groden","year":"1991","unstructured":"Groden LR, Murphy B, Rodnite J, Genvert GI (1991) Lid flora in blepharitis. Angew Chem Int Ed 6(11):951\u2013952","journal-title":"Angew Chem Int Ed"},{"key":"7025_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1073\/pnas.0407661102","volume":"102","author":"JS Wright","year":"2005","unstructured":"Wright JS, Jin R, Novick RP (2005) Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci U S A 102:1691\u20131696. https:\/\/doi.org\/10.1073\/pnas.0407661102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7025_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","volume":"94","author":"DL Opitz","year":"2011","unstructured":"Opitz DL, Tyler KF (2011) Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom 94:200\u2013206. https:\/\/doi.org\/10.1111\/j.1444-0938.2010.00540.x","journal-title":"Clin Exp Optom"},{"key":"7025_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/ICO.0B013E3181CA38A0","volume":"29","author":"RM Haque","year":"2010","unstructured":"Haque RM, Torkildsen GL, Brubaker K et al (2010) Multicenter open-label study evaluating the efficacy of Azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea 29:871\u2013877. https:\/\/doi.org\/10.1097\/ICO.0B013E3181CA38A0","journal-title":"Cornea"},{"key":"7025_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12325-008-0096-9","volume":"25","author":"J Luchs","year":"2008","unstructured":"Luchs J (2008) Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther 25:858\u2013870. https:\/\/doi.org\/10.1007\/s12325-008-0096-9","journal-title":"Adv Ther"},{"key":"7025_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12325-012-0018-8","volume":"29","author":"R Belfort","year":"2012","unstructured":"Belfort R, Gabriel L, Bispo PJM et al (2012) Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis. Adv Ther 29:416\u2013426. https:\/\/doi.org\/10.1007\/s12325-012-0018-8","journal-title":"Adv Ther"},{"key":"7025_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40123-021-00401-x","volume":"10","author":"FS Mah","year":"2021","unstructured":"Mah FS, Karpecki PM (2021) Review of loteprednol etabonate 0.5%\/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Ophthalmol Ther 10:859\u2013875. https:\/\/doi.org\/10.1007\/s40123-021-00401-x","journal-title":"Ophthalmol Ther"},{"key":"7025_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/S12886-024-03765-3","author":"H Siegel","year":"2024","unstructured":"Siegel H, Merz A, Gross N et al (2024) BlephEx-treatment for blepharitis: a prospective randomized placebo-controlled trial. BMC Ophthalmol. https:\/\/doi.org\/10.1186\/S12886-024-03765-3","journal-title":"BMC Ophthalmol"},{"key":"7025_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1461-1468.2004","volume":"48","author":"CK Hope","year":"2004","unstructured":"Hope CK, Wilson M (2004) Analysis of the effects of chlorhexidine on oral biofilm vitality and structure based on viability profiling and an indicator of membrane integrity. Antimicrob Agents Chemother 48:1461. https:\/\/doi.org\/10.1128\/AAC.48.5.1461-1468.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"7025_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/FMICB.2021.741863","volume":"12","author":"KA Gr\u00e4nicher","year":"2021","unstructured":"Gr\u00e4nicher KA, Karygianni L, Attin T, Thurnheer T (2021) Low concentrations of chlorhexidine inhibit the formation and structural integrity of enzyme-treated multispecies oral biofilms. Front Microbiol 12:741863. https:\/\/doi.org\/10.3389\/FMICB.2021.741863","journal-title":"Front Microbiol"},{"key":"7025_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/11206721221124684","volume":"33","author":"A Niro","year":"2022","unstructured":"Niro A, Pignatelli F, Fallico M et al (2022) Polyhexamethylene biguanide hydrochloride (PHMB)-properties and application of an antiseptic agent. A narrative review. Eur J Ophthalmol 33:655\u2013666. https:\/\/doi.org\/10.1177\/11206721221124684","journal-title":"Eur J Ophthalmol"},{"key":"7025_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jcjo.2024.01.012","volume":"59","author":"KA Stephenson","year":"2024","unstructured":"Stephenson KA, Merkur A, Kirker A et al (2024) Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection. Can J Ophthalmol 59:424\u2013429. https:\/\/doi.org\/10.1016\/j.jcjo.2024.01.012","journal-title":"Can J Ophthalmol"},{"key":"7025_CR21","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1093\/jac\/dks284","volume":"67","author":"C Horner","year":"2012","unstructured":"Horner C, Mawer D, Wilcox M (2012) Reduced susceptibility to chlorhexidine in staphylococci: is it increasing and does it matter? J Antimicrob Chemother 67:2547\u20132559. https:\/\/doi.org\/10.1093\/jac\/dks284","journal-title":"J Antimicrob Chemother"},{"key":"7025_CR22","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1128\/AAC.02419-14","volume":"58","author":"CD Schlett","year":"2014","unstructured":"Schlett CD, Millar EV, Crawford KB et al (2014) Prevalence of chlorhexidine-resistant methicillin-resistant Staphylococcus aureus following prolonged exposure. Antimicrob Agents Chemother 58:4404\u20134410. https:\/\/doi.org\/10.1128\/AAC.02419-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"7025_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.diagmicrobio.2008.11.014","volume":"63","author":"WH Sheng","year":"2009","unstructured":"Sheng WH, Wang JT, Lauderdale TL et al (2009) Epidemiology and susceptibilities of methicillin-resistant Staphylococcus aureus in taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol Infect Dis 63(3):309\u2013313. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2008.11.014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7025_CR24","first-page":"147","volume":"12","author":"G McDonnell","year":"1999","unstructured":"McDonnell G, ADRussell (1999) Antiseptics and disinfectants: Activity, action and resistance. J Intellect Property 12:147\u2013179","journal-title":"J Intellect Property"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07025-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:42:56Z","timestamp":1771573376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07025-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7025"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07025-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the \u201cMeir\u201d Medical Center Kfar-Saba and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of Interest"}}]}}